Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of unmet medical need. The company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, cardiovascular, hematology/oncology, and inflammation/respiratory.
As a large producer of HIV and Hepatitis treatments, Gilead recognized its ability to address health care inequities across the globe and has made improving access to medicine a central component of its corporate social responsibility platform. Managed directly at the board level, Gilead in partnership with relevant stakeholders, has created a variety of programs in many developing countries to galvanize lasting health improvements for those communities. These include, but are not limited to, licensing products to India, China, and South Africa and aiding in the development of more affordable generic options; as well as waiving royalty fees for pediatric product formulations, providing an incentive to develop more sensitive treatments appropriate for children’s use. In addition, Gilead provides competitive compensation packages and employee benefits, including stock plans, variable pay, and tuition reimbursements. Lastly, the company has some environmental improvement measures in place; these include more efficient packaging and distribution mechanisms and implementing green building at a number of the company’s facilities.
Gilead’s approach to quality management is largely based on compliance with relevant laws and regulations. For example, the company does not utilize formal certifications such as ISO 9001; furthermore, unlike some of its competitors, Gilead has not joined industry partnerships, such as Rx360, dedicated to product quality or supply chain security.
Industry: Health Care
Country: United States
To the best of our knowledge the above information is accurate and was obtained from sources we believe to be reliable. Neither the information presented above nor any opinion expressed shall be construed as an offer to sell or a solicitation to buy the security. The views expressed are those of portfolio management as of 12/31/16 and may not reflect current opinions or subsequent events.